• LAST PRICE
    3.5700
  • TODAY'S CHANGE (%)
    Trending Up0.0700 (2.0000%)
  • Bid / Lots
    3.0500/ 1
  • Ask / Lots
    4.8000/ 7
  • Open / Previous Close
    3.5000 / 3.5000
  • Day Range
    Low 3.4400
    High 3.7700
  • 52 Week Range
    Low 1.9500
    High 14.8600
  • Volume
    24,780
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 3.5
TimeVolumeXLO
09:32 ET3313.5
09:42 ET51003.49
09:44 ET6523.6
09:53 ET1003.56
10:26 ET2803.6188
10:27 ET1503.61
10:44 ET3003.5701
10:47 ET13003.65
10:49 ET1003.635
10:51 ET2003.645
10:58 ET7003.67
11:02 ET2003.77
11:07 ET1003.71
11:09 ET2753.71
11:12 ET4003.75
11:14 ET1003.71
11:23 ET30003.72
11:52 ET27023.71
12:15 ET32003.6384
12:19 ET19003.61
12:21 ET4003.6
12:37 ET1003.62
12:39 ET3003.61
12:44 ET1003.62
12:50 ET1003.62
12:57 ET1113.6115
01:26 ET1003.62
01:36 ET3003.63
02:02 ET1003.63
02:54 ET2003.615
03:57 ET1003.6
04:00 ET1003.57
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesXLO
Xilio Therapeutics Inc
96.2M
-1.1x
---
United StatesRVPH
Reviva Pharmaceuticals Holdings, Inc.
94.9M
-3.6x
---
United StatesACHV
Achieve Life Sciences Inc
93.1M
-1.3x
---
United StatesMYMD
MyMD Pharmaceuticals Inc
99.5M
-5.7x
---
United StatesEVLO
Evelo Biosciences Inc
99.7M
-0.5x
---
United StatesNCNA
NuCana PLC
84.6M
-2.3x
---
As of 2023-02-07

Company Information

Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by tumor microenvironment (TME)-associated proteases.

Contact Information

Headquarters
828 Winter Street, Suite 300WALTHAM, MA, United States 02451
Phone
617-430-4680
Fax
302-655-5049

Executives

Chairman of the Board
Paul Clancy
Non-Executive Independent Chairman of the Board
Yuan Xu
President, Chief Executive Officer, Director
Rene Russo
President
Martin Huber
Chief Operating Officer
Joseph Farmer

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$96.2M
Revenue (TTM)
$0.00
Shares Outstanding
27.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-3.14
Book Value
$6.78
P/E Ratio
-1.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.